Compare Biogen Inc (BIIB) vs Rush Street Interactive Inc (RSI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Rush Street Interactive Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Rush Street Interactive Inc trades at $24.24 (market cap $2.91B). The key difference: Biogen Inc is far larger — about 10.4× Rush Street Interactive Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | RSI | |
|---|---|---|
Market Cap | $30.13B | $2.91B |
Sector | Health | Technology |
52-Week High | $216.63 | $34.52 |
52-Week Low | $128.93 | $15.89 |
Enterprise Value | $37.20B | $2.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Rush Street Interactive (RSI) trades at $24.28, down 1.78% over 24 hours, with a bearish technical signal from moving averages despite bullish oscillators. The company reported record Q2 2026 revenue of $393.8 million, up 46% year-over-year, and raised full-year guidance. Financials show strong revenue growth but thin net margins of 2.33%, with elevated valuation ratios like a P/E of 81.13. Analyst consensus is strongly bullish with a $34.75 price target.
The outlook is positive due to robust revenue growth and expansion in online casino and sports betting markets, but risks include high valuation sensitivity and competitive pressures. Institutional buying by firms like Dimensional Fund Advisors supports sentiment, though insider selling post-rally warrants monitoring. The stock offers growth potential if execution continues, but investors should weigh margin pressures against expansion prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Rush Street Interactive Inc
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →
